Aclaris Therapeutics ACRS Net unrealized gains (losses) on securities still held
Net unrealized gains (losses) on securities still held at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's net unrealized gains (losses) on securities still held.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's net unrealized gains (losses) on securities still held?
- Aclaris Therapeutics (ACRS) reported net unrealized gains (losses) on securities still held of -$588K in Q1 2026.
- How has Aclaris Therapeutics's net unrealized gains (losses) on securities still held changed year-over-year?
- Aclaris Therapeutics's net unrealized gains (losses) on securities still held decreased by 274.5% year-over-year, from $337K to -$588K.
- What is the long-term trend for Aclaris Therapeutics's net unrealized gains (losses) on securities still held?
- Over 2 years (2021 to 2025), Aclaris Therapeutics's net unrealized gains (losses) on securities still held has grown at a 49.7% compound annual growth rate (CAGR), from -$229K to $513K.
- What does net unrealized gains (losses) on securities still held mean?
- Reflects the change in the market value of investment securities held by the company that have not yet been sold. This metric captures the volatility of the company's investment portfolio due to market fluctuations rather than core business operations. It is an important indicator of the unrealized financial impact of the company's treasury and capital allocation strategy.